Cannabinoid research and development company AXIM® Biotechnologies, Inc. has retained the services of global contract research organization Ora®, Inc. to perform the company's upcoming product development and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics.
Ora will reportedly run the clinical programs under the supervision of Prof. Robert Ritch, surgeon director emeritus and chief of Glaucoma Services at New York Eye and Ear Infirmary of Mount Sinai School of Medicine in New York (NYEE).
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: AXIM® Biotechnologies, Inc.